Open Access Open Access  Restricted Access Subscription or Fee Access

The proposal of a clinical protocol to assess central and peripheral fatigue in myotonic dystrophy type 1

S. Baldanzi, G. Ricci, M. Bottari, L. Chico, C. Simoncini, G. Siciliano

Abstract


DM1 is an autosomal-dominant disorder characterized by muscle weakness, myotonia, and multisystemic involvement. According to current literature fatigue and daytime sleepiness are among the main symptoms of DM1. Oxidative stress has been proposed to be one of the pathogenic factors of fatigue consequent to DM1.

In this study, we investigated the dimensions of experienced fatigue and  physiological fatigue in a sample of 26 DM1 patients (17 males, 9 females, mean age 41.6 years, SD ± 12.7); experienced fatigue has been studied through Fatigue Severity Scale (FSS), and physiological fatigue was measured through an intermittent incremental exercise of the forearm muscles using a myometer; oxidative stress balance markers trend during aerobic exercise test have been collected. The occurrence of central fatigue in the sample means that central activation worsens during the motor contraction; interestingly FSS score was significantly correlated to MVC (before and after the effort, r-before = -0.583, p < 0.01, r-after= -0.534, p < 0.05), and to motor disability measured by MRC (r = -0.496, p < 0.05); moreover we found a strong tendency towards significance in the association to lactate baseline (r = 0.378, p = 0.057).

Results are discussed to define whether or not, based on clinical and laboratory grounds, such exercise training protocol may be suitable for proper management of DM1 patients; proper assessment of fatigue should be included in algorithms for data collection in DM1 patient registries.


Keywords


Neuromuscolar, Central/Peripheral, Fatigue

Full Text:

PDF

References


• Allen DG, Lamb GD, Westerblad H. Skeletal muscle fatigue: cellular mechanisms. Physiol Rev. 2008 Jan;88(1):287-332.

• Angelini C, Tasca E. Fatigue in muscular dystrophies. Neuromuscul Disord. 2012 Dec;22 Suppl 3:S214-20.

• Baldanzi S, Bevilacqua F, Lorio R, Volpi L, Simoncini C, Petrucci A, Cosottini M, Massimetti G, Tognoni G, Ricci G, Angelini C, Siciliano G. Disease awareness in myotonic dystrophy type 1: an observational cross-sectional study. Orphanet J Rare Dis. 2016 Apr 4;11:34.

• Boërio D, Lefaucheur JP, Bassez G, Hogrel JY. Central and peripheral components of exercise-related fatigability in myotonic dystrophy type 1. Acta Neurol Scand. 2012 Jan;125(1):38-46.

• Bray SR, Graham JD, Martin Ginis KA, Hicks AL. Cognitive task performance causes impaired maximum force production in human hand flexor muscles. Biol Psychol. 2012 Jan;89(1):195-200.

• Carrasco M1, Canicio J, Palacín M, Zorzano A, Kaliman P. Identification of intracellular signaling pathways that induce myotonic dystrophy protein kinase expression during myogenesis. Endocrinology. 2002 Aug;143(8):3017-25.

• Finsterer J, Stollberger C, Blazek G, Kunafer M & Prager E. Cardiac involvement over 10 years in myotonic and Becker muscular dystrophy and mitochondrial disorder. Int J Cardiol 2007;119: 176–184.

• Flachenecker P1, Kümpfel T, Kallmann B, Gottschalk M, Grauer O, Rieckmann P, Trenkwalder C, Toyka KV. Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler. 2002 Dec;8(6):523-6.

• Franzini M, Fornaciari I, Siciliano G, Volpi L, Ricci G, Marchi S, Gagliardi G, Baggiani A, Torracca F, Fierabracci V, Miccoli M, Pompella A, Emdin M, Paolicchi A. Serum gamma-glutamyltransferase fractions in myotonic dystrophy type I: differences with healthy subjects and patients with liver disease. Clin Biochem. 2010 Oct;43(15):1246-8.

• Gandevia SC. Spinal and supraspinal factors in human muscle fatigue. Physiol Rev. 2001 Oct;81(4):1725-89.

• Heydemann A, McNally E. NO more muscle fatigue. J Clin Invest. 2009 Mar;119(3):448-50.

• Harper PS (2001). Major Problems in Neurology: Myotonic Dystrophy. London UK: WB Saunders; 2001.

• Hermans MC, Merkies IS, Laberge L, Blom EW, Tennant A, Faber CG. Fatigue and daytime sleepiness scale in myotonic dystrophy type 1. Muscle Nerve. 2013 Jan;47(1):89-95.

• Huang CC, Kuo HC. Myotonic dystrophies. Chang Gung Med J. 2005; 28(8):517-26.

• Jorde L, Carey J, Bamshad M & White R. Medical Genetics 2006. St Louis: Mosby, 80–81.

• Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep, 14(6):540-545.

• Kalkman JS, Schillings ML, Zwarts MJ, van Engelen BG, Bleijenberg G. The development of a model of fatigue in neuromuscular disorders: a longitudinal study. J Psychosom Res. 2007 May;62(5):571-9.

• Kalkman JS, Schillings ML, van der Werf SP, Padberg GW, Zwarts MJ, van Engelen BG, Bleijenberg G. Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy, and HMSN-I. J Neurol Neurosurg Psychiatry. 2005 Oct;76(10):1406-9.

• Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989 Oct;46(10):1121-3.

• Kuwahara H, Horie T, Ishikawa S, Tsuda C, Kawakami S, Noda Y, Kaneko T, Tahara S, Tachibana T, Okabe M, Melki J, Takano R, Toda T, Morikawa D, Nojiri H, Kurosawa H, Shirasawa T, Shimizu T. Oxidative stress in skeletal muscle causes severe disturbance of exercise activity without muscle atrophy. Free Radic Biol Med. 2010 May 1;48(9):1252-62.

• Laberge L, Gagnon C, Jean S, Mathieu J. Fatigue and daytime sleepiness rating scales in myotonic dystrophy: a study of reliability. J Neurol Neurosurg Psychiatry. 2005 Oct;76(10):1403-5.

• Laberge L, Dauvilliers Y, Bégin P, Richer L, Jean S, Mathieu J. Fatigue and daytime sleepiness in patients with myotonic dystrophy type 1: to lump or split? Neuromuscul Disord. 2009 Jun;19(6):397-402.

• Leelarungrayub D, Khansuwan R, Pothongsunun P, Klaphajone J. N-acetylcysteine supplementation controls total antioxidant capacity, creatine kinase, lactate, and tumor necrotic factor-alpha against oxidative stress induced by graded exercise in sedentary men. Oxid Med Cell Longev. 2011;2011:329643.

• Lezak MD, Howieson DB, Bigler ED, Tranel D. Neuropsychological Assessment, 5th edn. Oxford, UK: Oxford University Press, 2012.

• Mathieu J, Boivin H, Meunier D, Gaudreault M, Bègin P. Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology 2001; 56(3):336-40.

• Meola G, Sansone V. Cerebral involvement in myotonic dystrophies. Muscle Nerve 2007; 36(3):294-306.

• Milner-Brown HS, Stein RB, Yemm R. Changes in firing rate of human motor units during linearly changing voluntary contractions. J. Physiol. 230:371-390.

• Montes J, Dunaway S, Montgomery MJ, Sproule D, Kaufmann P, De Vivo DC, Rao AK. Fatigue leads to gait changes in spinal muscular atrophy. Muscle Nerve. 2011 Apr;43(4):485-8.

• Moxley RT 3rd, Meola G, Udd B, Ricker K. Report of the 84th ENMC workshop: PROMM (proximal myotonic myopathy) and other myotonic dystrophy-like syndromes: 2nd workshop. 13-15th October, 2000, Loosdrecht, The Netherlands. Neuromuscul Disord. 2002; 12(3):306-17.

• Ono S, Kurisaki H, Inouye K, Mannen T. Ragged-red fibers in myotonic dystrophy J Neurol Sci 1986;74:247-55.

• Ørngreen MC, Olsen DB, Vissing J. Aerobic Training in Patients with Myotonic Dystrophy Type 1. Ann Neurol 2005;57:754–757.

• Pantic B, Trevisan E, Citta A, et al. Myotonic dystrophy protein kinase (DMPK) prevents ROS-induced cell death by assembling a hexokinase II-Src complex on the mitochondrial surface. Cell Death and Disease 2013;4:1-11.

• Peric S, Stojanovic VR, Basta I, Peric M, Milicev M, Pavlovic S, Lavrnic D. Influence of multisystemic affection on health-related quality of life in patients with myotonic dystrophy type 1. Clin Neurol Neurosurg. 2013 Mar;115(3):270-5.

• Reid SF, Chalder T, Cleare A, Hotopf M, Wessely S. Chronic fatigue syndrome. BMJ Clin Evid. 2008 Aug 28;2008. pii: 1101. Review.

• Reitan R. M. (1958). Validity of the Trail Making test as an indicator of organic brain damage. Percept. Mot Skills, 8, 271-276.

• Sansone VA, Panzeri M, Montanari M, Apolone G, Gandossini S, Rose MR, Politano L, Solimene C, Siciliano G, Volpi L, Angelini C, Palmieri A, Toscano A, Musumeci O, Mongini T, Vercelli L, Massa R, Panico MB, Grandi M, Meola G. Italian validation of INQoL, a quality of life questionnaire for adults with muscle diseases. Eur J Neurol. 2010 Sep;17(9):1178-87.

• Sansone VA, Ricci C, Montanari M, Apolone G, Rose M, Meola G, INQoL Group. Measuring quality of life impairment in skeletal muscle channelopathies. Eur J Neurol. 2012; Nov;19(11):1470-6.

• Siciliano G, Manca M, Gennarelli M, Angelini C, Rocchi A, Iudice A, Miorin M, Mostacciuolo M. Epidemiology of myotonic dystrophy in Italy: re-apprisal after genetic diagnosis. Clin Genet. 2001 May;59(5):344-9.

• Søgaard K, Gandevia SC, Todd G, Petersen NT, Taylor JL. The effect of sustained low-intensity contractions on supraspinal fatigue in human elbow flexor muscles. J Physiol. 2006 Jun 1; 573(Pt 2): 511–523.

• Spinnler H, Tognoni G. Standardizzazione e taratura italiana di test neuropsicologici. Ital J Neurol Sci 1987; 8[Suppl]:1–120.

• Taylor JL, Gandevia SC. A comparison of central aspects of fatigue in submaximal and maximal voluntary contractions. J Appl Physiol (1985). 2008 Feb;104(2):542-50. Epub 2007 Nov 21.

• Taylor JL, Gandevia SC. Transcranial magnetic stimulation and human muscle fatigue. Muscle Nerve. 2001 Jan;24(1):18-29.

• Udd B. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol. 2012;11:891-905.

• Usuki F, Tagahashi N, Sasagawa N, Ishiura S. Differential signal pathways following oxidative stress in mutant Myotonin Protein Kinase cDNA-transfected C2C12 cell lines. Biochem Byophis Res Commun 2000;267:739-43.

• van Engelen B, OPTIMISTIC Consortium. Cognitive behaviour therapy plus aerobic exercise training to increase activity in patients with myotonic dystrophy type 1 (DM1) compared to usual care (OPTIMISTIC): study protocol for randomised controlled trial. Trials 2015. 16:224.


Refbacks

  • There are currently no refbacks.